New blood cancer drug Ojjaara/Omjjara generated £118 million in product sales compared with £98 million in third-quarter 2024 driven by continued strong uptake in the United States ...

So, Ojjaara/Omjjara sales amounted to $150 million in the fourth quarter of 2024, more than tripling year-on-year. While sales of the HIV therapy called Cabenuva also did not disappoint ...

New blood cancer drug Ojjaara/Omjjara generated £118 million in product sales compared with £98 million in third-quarter 2024 driven by continued strong uptake in the United States. Contributions from ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning, the UK ...

New blood cancer drug Ojjaara/Omjjara generated £118 million in product sales compared with £98 million in third-quarter 2024. While the drug was approved by the FDA in September 2023 ...